We are analyzing https://link.springer.com/article/10.1186/1471-2407-14-1.

Title:
Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition | BMC Cancer
Description:
Background Increased collagen deposition provides physical and biochemical signals to support tumor growth and invasion during breast cancer development. Therefore, inhibition of collagen synthesis and deposition has been considered a strategy to suppress breast cancer progression. Collagen prolyl-4-hydroxylase α subunit 2 (P4HA2), an enzyme hydroxylating proline residues in -X-Pro-Gly- sequences, is a potential therapeutic target for the disorders associated with increased collagen deposition. However, expression and function of P4HA2 in breast cancer progression are not well investigated. Methods Gene co-expression analysis was performed in the published microarray datasets to identify potential regulators of collagen I, III, and IV in human breast cancer tissue. Expression of P4HA2 was silenced by shRNAs, and its activity was inhibited by 1, 4-DPCA, a prolyl-4-hydroxylase inhibitor. Three-dimensional culture assay was used to analyze roles of P4HA2 in regulating malignant phenotypes of breast cancer cells. Reduced deposition of collagen I and IV was detected by Western blotting and immunofluorescence. Control and P4HA2-silenced breast cancer cells were injected into fat pad and tail vein of SCID mice to examine effect of P4HA2 on tumor growth and lung metastasis. Results Using gene co-expression analysis, we showed that P4HA2 was associated with expression of Col1A1, Col3A1, and Col4A1 during breast cancer development and progression. P4HA2 mRNA levels were significantly upregulated in breast cancer compared to normal mammary tissue. Increased mRNA levels of P4HA2 correlated with poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status. Silencing P4HA2 expression or treatment with the P4HA inhibitor significantly inhibited cell proliferation and suppressed aggressive phenotypes of breast cancer cells in 3D culture, accompanied by reduced deposition of collagen I and IV. We also found that knockdown of P4HA2 inhibited mammary tumor growth and metastasis to lungs in xenograft models. Conclusion These results suggest the critical role of P4HA2 in breast cancer progression and identify P4HA2 as a potential therapeutic target and biomarker for breast cancer progression.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, cells, pha, breast, collagen, pubmed, article, google, scholar, expression, cell, tumor, cas, mdamb, culture, figure, control, progression, central, deposition, knockdown, shpha, phasilenced, growth, dpca, levels, analysis, metastasis, human, invasion, proliferation, staining, reduced, significantly, cola, mrna, development, tissue, malignant, results, biol, showed, mice, tumors, size, increased, compared, mammary, matrix, vivo,

Topics {✒️}

sh-p4ha2-1 mda-mb-231/luc cells shp4ha2-1 mda-mb-231/luc cells collagen prolyl-4-hydroxylase resides control mda-mb-231/luc cells yap-dependent matrix remodelling pre-publication history p4ha2-silenced mda-mb-231 cells open access license vertebrate collagen prolyl-4-hydroxylases mda-mb-231/luc cells x-pro-gly- sequences x-pro-gly- sequences [17–20] matrix-attached cancer cells article download pdf prolyl-4-hydroxylase inhibitor phosphomolybdic-phosphotungstic acid solution mda-mb-231/luciferase cells mda-mb-231 cells compared 60 ml 1 mg/ml matrigel collagen prolyl-4-hydroxylase [16] 4-dpca treated mda-mb-157 cell-collagen interaction controls p4ha2-silenced mda-mb-157 post-transcription modification enzymes α subunit erbb2-negative breast cancers basement membrane serves treatment mda-mb-231 cells promote cell invasion tumor-stromal interface collagen prolyl hydroxylases p4ha2-silenced t4-2 cells form polarized acinar invasive breast carcinoma full size image erbb2-positive cancer tissues breast cancer progression breast ductal carcinoma tumor stromal microenvironment article xiong related subjects breast cancer compared human breast cancer breast cancer patients pre-cooled acetone martinez-cantarin mp privacy choices/manage cookies support tumor growth regulating cell proliferation inhibited tumor growth

Questions {❓}

Bissell MJ, Hines WC: Why don’t we get more cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition
         description:Increased collagen deposition provides physical and biochemical signals to support tumor growth and invasion during breast cancer development. Therefore, inhibition of collagen synthesis and deposition has been considered a strategy to suppress breast cancer progression. Collagen prolyl-4-hydroxylase α subunit 2 (P4HA2), an enzyme hydroxylating proline residues in -X-Pro-Gly- sequences, is a potential therapeutic target for the disorders associated with increased collagen deposition. However, expression and function of P4HA2 in breast cancer progression are not well investigated. Gene co-expression analysis was performed in the published microarray datasets to identify potential regulators of collagen I, III, and IV in human breast cancer tissue. Expression of P4HA2 was silenced by shRNAs, and its activity was inhibited by 1, 4-DPCA, a prolyl-4-hydroxylase inhibitor. Three-dimensional culture assay was used to analyze roles of P4HA2 in regulating malignant phenotypes of breast cancer cells. Reduced deposition of collagen I and IV was detected by Western blotting and immunofluorescence. Control and P4HA2-silenced breast cancer cells were injected into fat pad and tail vein of SCID mice to examine effect of P4HA2 on tumor growth and lung metastasis. Using gene co-expression analysis, we showed that P4HA2 was associated with expression of Col1A1, Col3A1, and Col4A1 during breast cancer development and progression. P4HA2 mRNA levels were significantly upregulated in breast cancer compared to normal mammary tissue. Increased mRNA levels of P4HA2 correlated with poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status. Silencing P4HA2 expression or treatment with the P4HA inhibitor significantly inhibited cell proliferation and suppressed aggressive phenotypes of breast cancer cells in 3D culture, accompanied by reduced deposition of collagen I and IV. We also found that knockdown of P4HA2 inhibited mammary tumor growth and metastasis to lungs in xenograft models. These results suggest the critical role of P4HA2 in breast cancer progression and identify P4HA2 as a potential therapeutic target and biomarker for breast cancer progression.
         datePublished:2014-01-02T00:00:00Z
         dateModified:2014-01-02T00:00:00Z
         pageStart:1
         pageEnd:12
         license:https://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/1471-2407-14-1
         keywords:
            Tumor microenvironment
            Breast cancer
            Collagen deposition
            Cancer progression
            Cell proliferation
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig6_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gaofeng Xiong
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lei Deng
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jieqing Zhu
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Piotr G Rychahou
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Kentucky
                     address:
                        name:Department of Surgery, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ren Xu
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Kentucky
                     address:
                        name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition
      description:Increased collagen deposition provides physical and biochemical signals to support tumor growth and invasion during breast cancer development. Therefore, inhibition of collagen synthesis and deposition has been considered a strategy to suppress breast cancer progression. Collagen prolyl-4-hydroxylase α subunit 2 (P4HA2), an enzyme hydroxylating proline residues in -X-Pro-Gly- sequences, is a potential therapeutic target for the disorders associated with increased collagen deposition. However, expression and function of P4HA2 in breast cancer progression are not well investigated. Gene co-expression analysis was performed in the published microarray datasets to identify potential regulators of collagen I, III, and IV in human breast cancer tissue. Expression of P4HA2 was silenced by shRNAs, and its activity was inhibited by 1, 4-DPCA, a prolyl-4-hydroxylase inhibitor. Three-dimensional culture assay was used to analyze roles of P4HA2 in regulating malignant phenotypes of breast cancer cells. Reduced deposition of collagen I and IV was detected by Western blotting and immunofluorescence. Control and P4HA2-silenced breast cancer cells were injected into fat pad and tail vein of SCID mice to examine effect of P4HA2 on tumor growth and lung metastasis. Using gene co-expression analysis, we showed that P4HA2 was associated with expression of Col1A1, Col3A1, and Col4A1 during breast cancer development and progression. P4HA2 mRNA levels were significantly upregulated in breast cancer compared to normal mammary tissue. Increased mRNA levels of P4HA2 correlated with poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status. Silencing P4HA2 expression or treatment with the P4HA inhibitor significantly inhibited cell proliferation and suppressed aggressive phenotypes of breast cancer cells in 3D culture, accompanied by reduced deposition of collagen I and IV. We also found that knockdown of P4HA2 inhibited mammary tumor growth and metastasis to lungs in xenograft models. These results suggest the critical role of P4HA2 in breast cancer progression and identify P4HA2 as a potential therapeutic target and biomarker for breast cancer progression.
      datePublished:2014-01-02T00:00:00Z
      dateModified:2014-01-02T00:00:00Z
      pageStart:1
      pageEnd:12
      license:https://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/1471-2407-14-1
      keywords:
         Tumor microenvironment
         Breast cancer
         Collagen deposition
         Cancer progression
         Cell proliferation
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-14-1/MediaObjects/12885_2013_Article_4231_Fig6_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gaofeng Xiong
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lei Deng
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jieqing Zhu
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Piotr G Rychahou
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Kentucky
                  address:
                     name:Department of Surgery, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ren Xu
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Kentucky
                  address:
                     name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:14
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Kentucky
      address:
         name:Markey Cancer Center, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Markey Cancer Center, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Markey Cancer Center, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Markey Cancer Center, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Department of Surgery, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Markey Cancer Center, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gaofeng Xiong
      affiliation:
            name:University of Kentucky
            address:
               name:Markey Cancer Center, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Lei Deng
      affiliation:
            name:University of Kentucky
            address:
               name:Markey Cancer Center, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Jieqing Zhu
      affiliation:
            name:University of Kentucky
            address:
               name:Markey Cancer Center, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Piotr G Rychahou
      affiliation:
            name:University of Kentucky
            address:
               name:Markey Cancer Center, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
            name:University of Kentucky
            address:
               name:Department of Surgery, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Ren Xu
      affiliation:
            name:University of Kentucky
            address:
               name:Markey Cancer Center, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
            name:University of Kentucky
            address:
               name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Markey Cancer Center, University of Kentucky, Lexington, USA
      name:Markey Cancer Center, University of Kentucky, Lexington, USA
      name:Markey Cancer Center, University of Kentucky, Lexington, USA
      name:Markey Cancer Center, University of Kentucky, Lexington, USA
      name:Department of Surgery, University of Kentucky, Lexington, USA
      name:Markey Cancer Center, University of Kentucky, Lexington, USA
      name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA

External Links {🔗}(224)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.49s.

LINK . SPRINGER . COM {}